Literature DB >> 9865596

Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine.

T Ben-Yedidia1, R Arnon.   

Abstract

In our previous studies on the development of synthetic peptide-based vaccines, we have evaluated flagellin from a Salmonella typhi vaccine strain as a carrier molecule for synthetic peptides derived from the influenza virus. The results indicated that the use of recombinant flagella, expressing defined influenza epitopes, is adequate for induction of protection against a challenge infection. It is of importance to show that previous exposure to the carrier does not induce suppression of the response to such vaccine. In the present study we demonstrate that the protective effect is not impaired by pre-immunization with either the carrier flagellin molecule alone or with the intact salmonella. The immune response was manifested both by the level of antibodies produced and by a proliferative cellular response, as well as by an efficient protection of the mice from a sub-lethal challenge infection. Since prior exposure to the carrier did not result in immune suppression, we conclude that Salmonella flagellin is a suitable carrier for synthetic peptide based vaccines.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865596     DOI: 10.1016/s0165-2478(98)00073-x

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  28 in total

1.  Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni.

Authors:  T Ben-Yedidia; R Tarrab-Hazdai; D Schechtman; R Arnon
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.

Authors:  John T Bates; Aaron H Graff; James P Phipps; Jason M Grayson; Steven B Mizel
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

3.  Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses.

Authors:  Camilo Cuadros; Francisco J Lopez-Hernandez; Ana Lucia Dominguez; Michael McClelland; Joseph Lustgarten
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

4.  A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.

Authors:  Kristen N Delaney; James P Phipps; John B Johnson; Steven B Mizel
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

5.  Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.

Authors:  Bao-Zhong Wang; Harvinder S Gill; Sang-Moo Kang; Li Wang; Ying-Chun Wang; Elena V Vassilieva; Richard W Compans
Journal:  Clin Vaccine Immunol       Date:  2012-05-30

Review 6.  Effects of flagellin on innate and adaptive immunity.

Authors:  Anna N Honko; Steven B Mizel
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Flagellin as an adjuvant: cellular mechanisms and potential.

Authors:  Steven B Mizel; John T Bates
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

8.  Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.

Authors:  Steven B Mizel; Aaron H Graff; Nammalwar Sriranganathan; Sean Ervin; Cynthia J Lees; Mark O Lively; Roy R Hantgan; Michael J Thomas; James Wood; Brian Bell
Journal:  Clin Vaccine Immunol       Date:  2008-11-05

9.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

10.  Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112ΔiglB::fljB.

Authors:  Aimee L Cunningham; Kim Minh Dang; Jieh-Juen Yu; M Neal Guentzel; Hans W Heidner; Karl E Klose; Bernard P Arulanandam
Journal:  Vaccine       Date:  2014-07-19       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.